血管紧张素受体阻断:立体定向放射外科治疗后症状性放射性坏死的新方法
该研究纳入2002至2015年接受立体定向放射外科治疗的228例患者(111例脑转移瘤切除术后、117例动静脉畸形),分析血管紧张素阻断治疗(ABT)与症状性放射性坏死(SRN)的关联。ABT组在两组人群中1年SRN率均较低,且总生存和颅内疗效相似。作者认为ABT可能降低SRN风险,需前瞻性试验验证。
要点
- ABT与脑转移瘤切除术后SRS后1年SRN率降低相关(3.1% vs 25.3%,p=0.003)。
- ABT与动静脉畸形SRS后1年SRN率较低相关(6.7% vs 14.6%,p=0.063),未达统计学显著。
- 多因素分析中ABT为脑转移瘤SRN的显著预测因素(HR 0.17,95%CI 0.03-0.88,p=0.035)。
核心结论
- ABT使用似乎与SRS后SRN风险降低相关,且不损害总生存或颅内疗效。
- 作者认为需要前瞻性试验来验证这些发现。
研究设计与样本
- 研究纳入2002至2015年接受SRS的228例连续患者,其中111例为脑转移瘤切除术后(rBM),117例为动静脉畸形(AVM)。
- ABT队列定义为在SRS期间及1个月随访时正在接受血管紧张素阻断治疗。
- 采用Kaplan-Meier法和累积发生率模型分析总生存和颅内结局。
主要发现
- 总体51例(22.4%)患者属于ABT组:rBM组32例(28.8%),AVM组19例(16.2%)。
- rBM组中ABT组Graded Prognostic Analysis评分3-4的比例为25.0%,非ABT组为49.0%(p=0.033)。
- AVM组中ABT组中位年龄为51.4岁,非ABT组为35.4岁(p<0.001)。
- 两组人群中总生存和颅内疗效(rBM局部控制、AVM闭塞率)在队列间统计学相似。
- ABT与两组人群较低的1年SRN率相关:rBM组3.1% vs 25.3%(p=0.003);AVM组6.7% vs 14.6%(p=0.063)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preclinical evidence suggests angiotensin blockade therapy (ABT) decreases late radiation toxicities. This study aims to investigate the association between ABT and symptomatic radiation necrosis (SRN) following stereotactic radiosurgery (SRS). Resected brain metastases (rBM) and arteriovenous malformation (AVM) patients treated with SRS from 2002 to 2015 were identified. Patients in the ABT cohort were on therapy during SRS and at 1-month follow up. Kaplan Meier method and cumulative incidence model were used to analyze overall survival (OS) and intracranial outcomes. 228 consecutive patients were treated with SRS: 111 with rBM and 117 with AVM. Overall, 51 (22.4%) patients were in the ABT group: 32 (28.8%) in the rBM and 19 (16.2%) in AVM cohorts. Baseline characteristics were similar, except for higher Graded Prognostic Analysis (3-4) in the rBM (ABT: 25.0% vs. non-ABT: 49.0%, p = 0.033) and median age in the AVM (ABT: 51.4 vs. non-ABT: 35.4, p < 0.001) cohorts. In both populations, OS and intracranial efficacy (rBM-local control; AVM-obliteration rates) were statistically similar between the cohorts. ABT was associated with lower 1-year SRN rates in both populations: rBM, 3.1 versus 25.3% (p = 0.003); AVM, 6.7 vs. 14.6% (p = 0.063). On multivariate analysis, ABT was a significant predictive factor for rBM (HR: 0.17; 95% CI 0.03-0.88, p = 0.035), but did not reach statistical significance for AVM (HR: 0.36; 95% CI 0.09-1.52, p = 0.165). ABT use appears to be associated with a reduced risk of SRN following SRS, without detriment to OS or intracranial efficacy. A prospective trial to validate these findings is warranted.
引用
- Chowdhary M, Okwan-Duodu D, Switchenko JM, et al. Angiotensin receptor blockade: a novel approach for symptomatic radiation necrosis after stereotactic radiosurgery. J Neurooncol. 2017. PMID: 29124649. doi:10.1007/s11060-017-2652-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。